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Abstract
Background In preoperative blood management of colorectal
cancer patients, intravenous iron therapy is increasingly used
to treat anaemia and prevent red blood cell transfusions.
However, while iron deficiency is the most common cause
of anaemia, little is known about the prevalence and namely
type of iron deficiency in this population, whereas both types
of iron deficiency (i.e. absolute and functional iron deficiency)
are recommended to be treated differently by international
cancer guidelines.
Objective The aim of present study is to investigate the prev-
alence and namely type of iron deficiency in colorectal cancer
patients, and to assess its clinical relevance.
Methods Preoperative iron status, clinical parameters (i.e. age,
ASA classification, tumour location, tumour stage) and post-
operative complications were retrospectively collected for all
newly diagnosed colorectal cancer patients in our institution
over a 3-year period.
Results Iron deficiency was observed in 163 (48.1%) of 339
patients. Of these iron-deficient patients, 3.7% had an isolated
absolute iron deficiency (AID) and 15.3% a functional iron
deficiency (FID), while the rest had a combination of AID and
FID. Anaemia was present in 66.1% of iron-deficient patients.
Iron deficiency was significantly associated with an increased
postoperative complication rate (univariable OR 1.94,
p = 0.03, multivariable OR 1.84, p = 0.07), with right-sided
tumours (p < 0.001), high ASA classification (p = 0.002),
advanced tumour stage (p = 0.01) and advanced age
(p = 0.04). In comparing clinical parameters between patients
with AID and FID, advanced age was significantly associated
with FID (p = 0.03), and the presence of anaemia with AID
(p = 0.02).
Conclusion In preoperative colorectal cancer patients, there is
a high prevalence of iron deficiency, including a high percent-
age of patients with—a component of—functional iron defi-
ciency, associated with the increased postoperative complica-
tion rate. As both types of iron deficiency require a different
treatment strategy, our results illustrate the therapeutic poten-
tial of especially intravenous iron supplementation in patients
with severe iron deficiency and stress the urgency of routinely
monitoring preoperative iron status and differentiation be-
tween types of iron deficiency. As iron therapy may also be
potentially harmful in respect to stimulation of tumour growth,
future clinical trials assessing the long-term effect of iron ther-
apy are necessary.
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Introduction
Preoperative anaemia is frequently observed in colorectal can-
cer patients, with reported case incidences of > 30% [1].
Preoperative anaemia generally is associated with increased
postoperative morbidity and mortality [2] and is also reported
to be a cause of inferior long-term outcome, possibly by wors-
ening of tumour hypoxia [3, 4]. Furthermore, preoperative
anaemia is associated with increased utilisation of allogeneic
red blood cell (RBC) transfusion, which, for its part, is also
associated with deleterious effects on the short- and long-term
outcome in colorectal cancer patients [5, 6].
Iron deficiency (ID) is the most common cause of preop-
erative anaemia in colorectal cancer patients [7]. Contributing
mechanisms to the development iron deficiency anaemia in-
clude chronic tumour-induced blood loss and impaired iron
homeostasis associated with chronic disease. While chronic
blood loss will deplete iron stores and cause absolute iron
deficiency (AID), functional iron deficiency (FID) is
characterised by both reduced iron uptake in the gut and se-
questration in the reticulo-endothelial system of absorbed
iron, resulting in a reduction of biologically available iron
[8]. Next to AID, FID is the second most prevalent cause of
anaemia. FID is especially known from patients with immune
activation and therefore termed as anaemia of inflammation of
anaemia of chronic disease.
The importance of this differentiation lies in the fact that the
indication for initiation and the administration route of iron ther-
apy differ between AID and FID [9]. In patients with AID, iron
therapy is recommended to be started independently of the ac-
tual haemoglobin (Hb) level, while in patients with FID, iron
therapy is advised only if patients are symptomatic because of
iron deficiency and/or anaemia and should be withheld in pa-
tients with high ferritin levels (i.e. > 1000 ng/mL). In addition,
in patients with FID, oral iron is poorly absorbed in the duode-
num, while intravenous iron is more effective. On the other
hand, restrictive iron therapy might be advisable for cancer pa-
tients in general, as iron is reported to stimulate tumour growth.
The latter could be even more important for cancer patients with
FID. This cancer-induced immune response namely might well
protect against proliferation of tumour cells [8, 10].
Notwithstanding possible detrimental effects, iron in pre-
operative blood management to reverse the anaemia-
associated prognosis has gained more attention [11]. In partic-
ular, this has led to the increased use of preoperative intrave-
nous iron supplementation. Whereas preoperative anaemia is
a well-known and frequent complication in colorectal cancer
patients, little is known about the prevalence of iron deficien-
cy [7, 12]. While research is being carried out on the efficacy
of preoperative oral and intravenous iron therapy in patients
with iron deficiency anaemia, no trials differentiate between
AID and FID and often only the Hb increase and reduction in
RBC transfusions are studied [13, 14].
Despite the recommendations by international oncological
guidelines [15, 16], routinely monitoring preoperative iron
status is often not standard of care and is, for example, not
incorporated into the Dutch guideline on the treatment of
anaemia in oncological patients. The aim of present study is
to identify the prevalence and type of iron deficiency, and to
assess the clinical relevance of iron deficiency.
Methods
All patients undergoing resection for colorectal cancer between
1 July 2013 and 1 July 2016 at the Department of Surgery,
Reinier de Graaf Hospital, were eligible for inclusion. In these
patients, the inclusion criterion was the availability of iron
status (i.e. iron, transferrin, transferrin saturation, ferritin), mea-
sured directly after colonoscopy and suspicion of colorectal
cancer. Clinical and pathological data, including age, gender,
ASA classification, tumour type, pathological tumour stage,
neoadjuvant treatment and 30-day overall postoperative com-
plications (i.e. pulmonic, cardiologic, thrombotic, infectious,
neurologic), were collected by the Dutch Surgical Colorectal
Audit (DSCA), a disease-specific national audit. This audit
collects information on patient, tumour, treatment, and 30-
day and in-hospital outcome characteristics of all patients un-
dergoing a resection for primary colorectal carcinoma in the
Netherlands. The data set is based on evidence-based guide-
lines and is cross-checked on a yearly basis with data from the
Netherlands Cancer Registry. In addition, haemoglobin values
(i.e. at diagnosis, preoperative and postoperative), and iron
status at diagnosis, were retrospectively collected.
According to theWorld Health Organization (WHO), anae-
mia was defined as Hb < 8 mmol/L in men and < 7.5 mmol/L
in women. Iron deficiency was defined as transferrin satura-
tion (TSAT) < 20% andwas further classified as AID, FID or a
combination of both conditions. AID was defined as TSAT
< 20% and increased transferrin (> 3.6 g/L) and FID as TSAT
< 20%, reduced to normal transferrin and increased ferritin
(> 200 μg/L).
Tumour locations were classified as the right colon (i.e.
cecum, colon ascendens, hepatic flexure), transverse colon,
left colon (i.e. splenic flexure, colon descendens, sigmoid)
and rectum. Tumour staging and tumour grading were deter-
mined according to the AJCC recommendations in colorectal
cancer and were given by pathologic examination. The ASA
physical status classification system was used for assessing
the fitness of patients before surgery.
The results are mainly illustrated by descriptive statistics.
χ2, Fisher’s exact and Student’s t tests were used to compare
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the frequencies of both categorical and continuous variables
with iron status (i.e. iron deficiency versus non-iron deficien-
cy and absolute versus functional iron deficiency) and tumour
location (i.e. colon versus rectum). Binary logistic regression
analysis was performed to identify the relationship between
iron deficiency at diagnosis and postoperative complication.
All variables in the univariable analysis were included in the
multivariable analysis. A significance level of 0.05 was con-
sidered to be statistically significant.
Approval by the local medical ethics committee was ob-
tained. Our institution, a teaching hospital, is making use of
opt-out consent. Each included patients had given consent by
not declining to give consent.
Results
Incidence of iron deficiencies
In total, 429 patients underwent surgery for colorectal cancer,
and iron status was available in 339 patients (all measured at
diagnosis). Table 1 shows the baseline characteristics of in-
cluded patients. The mean age at presentation was 69.6 (range
28–95); 185 males and 154 females were included. Most pa-
tients (58.1%) were classified as ASA 2 and the most frequent
site of tumour occurrence was the left colon (36.6%), followed
by the rectum (29.5%), right colon (25.4%) and transverse
colon (8.6%). The majority of patients were classified as
pTNM stage 2 (33.6%), followed by stage 1 (29.8%), stage
3 (28.0%) and stage 4 (8.6%). Of 339 patients, preoperatively,
35 patients (10.3%) received radiotherapy alone, 19 patients
(5.6%) received concomitant chemoradiotherapy and 8 pa-
tients (2.4%) received chemotherapy alone. In total, 256 pa-
tients (79.0%) were symptomatic at presentation; most pa-
tients presented with blood loss (n = 108), followed by change
in stool (n = 72), other (n = 43) (i.e. abdominal pain, weight
loss, fatigue) and anaemia (n = 33). Iron deficiency was ob-
served in 163 patients (48.1%) and anaemia in 115 patients
(33.9%). Among these iron-deficient patients, 6 (3.7%) and 25
(15.3%) patients were absolute and functional iron deficient,
respectively. In the majority of patients (n = 132; 81.0%), iron
deficiency was caused by a combination of AID and FID. In
total, 80% of anemic patients had some form of iron deficien-
cy (5.2% AID, 9.6% FID, 65.2% combination AID and FID).
Of non-anemic patients, 14 (6.3%) were functional iron defi-
cient, and 57 (25.4%) had a combination of AID and FID; no
patients were absolute iron deficient (Fig. 1).
Associations between iron deficiency and patient
and tumour characteristics
In Table 2, the proportion of patients with and without iron
deficiency is given in relation to gender, age, ASA
classification, tumour location, pTNM stage and the presence
of anaemia. Iron deficiency was significantly more likely to
Table 1 Patient baseline characteristics (n = 339)
Number Percent
Gender
Male 185 54.6
Female 154 45.4
Age (years)
Mean (range) 69.63 (28–95)
ASA classification
I 76 22.4
II 197 58.1
III 65 19.2
IV 1 0.3
Tumour location
Right colon 86 25.4
Transverse colon 29 8.6
Left colon 124 36.6
Rectum 100 29.5
Neoadjuvant treatment
Chemotherapy 8 2.4
Radiotherapy 35 10.3
Concomitant chemoradiotherapy 19 5.6
None 277 81.7
pTNM stagea
I 101 29.8
II 114 33.6
III 95 28.0
IV 29 8.6
Presenting symptoms
Asymptomatic (population screening) 68 21.0
Symptomatic 256
Blood loss 108 33.3
Change in stool 72 22.2
Workup of anaemia 33 10.2
Other 43 13.3
Unknown 15
Iron deficiency
No 176 51.9
Yes 163 48.1
Absolute iron deficiency 6 3.7
Functional iron deficiency 25 15.3
Both conditions 132 81.0
Anaemia at presentation
No 224 66.1
Yes 115 33.9
Absolute iron deficiency 6 5.2
Functional iron deficiency 11 9.6
Both conditions 75 65.2
a After chemo and/or radiotherapy in 62 patients
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occur in the right colon (p < 0.001), in patients with a more
advanced pTNM stage (p = 0.01), in patients with a higher
ASA classification (p = 0.002) and in patients with more ad-
vanced age (p = 0.043). Moreover, anaemia was significantly
more observed in iron-deficient patients (p < 0.001). Gender
did not show a significant association with the presence of
iron deficiency. Iron-deficient patients presented more often
in the workup of anaemia, as compared to non-iron-deficient
patients (16.2 versus 4.7%), while non-iron-deficient patients
more often were diagnosed due to the screening program.
In Table 3, the mentioned variables (i.e. gender, age,
tumour location, ASA classification, pTNM stage and
anaemia) were compared between patients with AID and
those with FID. Results showed that advanced age was
significantly associated with FID (p = 0.03), while the
presence of anaemia was significantly associated with
AID (p = 0.02). Gender, tumour location, ASA classifica-
tion and pTNM stage were not found to have any signifi-
cant relationship with AID or FID.
Association between iron deficiency and postoperative
complication
In Table 4, the association between iron deficiency and post-
operative complications is assessed by uni- and multivariable
logistic regression analysis. In total, postoperative complica-
tions were observed in 75 of 339 patients. Initially, in
univariable analysis, the categorical variable of severity of
iron deficiency was included (i.e. no iron deficiency versus
mild iron deficiency (TSAT < 20%) versus severe iron defi-
ciency (TSAT < 10%)). As merely severe iron deficiency ap-
peared to be significantly associated with postoperative com-
plications (OR 1.92, p = 0.045, versus mild iron deficiency
OR 0.97, p = 0.92), severe iron deficiency was included in
uni- and multivariable logistic regression analyses, as shown
in Table 4. In univariable analysis, severe iron deficiency was
Fig. 1 Prevalence of iron deficiency
Table 2 Characteristics non-iron deficiency versus iron deficiency
Non-iron
deficiency
Iron
deficiency
p value
Number, n (%) 176 163
Gender, % 0.13
Male 58.5 50.3
Female 41.5 49.7
Age (years) 0.043
Mean ± SD 68.5 ± 10.86 70.8 ± 10.56
ASA, % 0.002
I + II 86.9 76.3
III + IV 13.1 26.4
Tumour location, % < 0.001
Right colon 13.6 38
Transverse colon 8.5 8.6
Left colon 39.8 33.1
Rectum 38.1 20.2
pTNM stage, % 0.01
I 36.9 22.1
II 27.3 40.5
III 28.4 27.6
IV 7.4 9.8
Anaemia at diagnosis, n (%) 23 (13.1) 92 (56.4) < 0.001
Presenting symptoms, n (%) < 0.001
Asymptomatic 47 (27.6) 21 (13.6)
Symptomatic 123 133
Blood loss 60 (35.3) 48 (31.2)
Change in stool 41 (24.1) 31 (20.1)
Workup of anaemia 8 (4.7) 25 (16.2)
Other 14 (8.2) 29 (18.8)
Table 3 Characteristics in absolute versus functional iron deficiency
Absolute iron
deficiency
Functional iron
deficiency
p value
Number, n 6 25
Gender, % 0.79
Male 66.7 72
Female 33.3 28
Age (years) 0.03
Mean ± SD 68.5 ± 4.23 74.2 ± 7.40
Tumour location, % 0.64
Colon 83.3 68.0
Rectum 16.7 32.0
ASA, % 0.60
I + II 66.7 80.0
III + IV 33.3 20.0
pTNM stage, % 0.66
I + II 66.7 52.0
III + IV 33.3 48.0
Anaemia, % 0.02
No 0 56.0
Yes 100 44.0
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significantly associated with postoperative complications (OR
1.94, p = 0.030). No significant result was found in multivar-
iable analysis (OR 1.84, p = 0.074).
Distinction between colon and rectum tumours
In Table 5, the different variables between colon and rectum
tumours are shown. Anaemia, both at diagnosis, preoperative
and postoperative, was more prevalent in colon tumours
(p < 0.001, p < 0.001, p = 0.04, respectively). Reduced Hb
levels at diagnosis, preoperative and postoperative were found
to be significantly associated with colon tumours (all
p < 0.001), while a reduction in the Hb level due to surgery
was more pronounced in patients with rectum tumours as
compared to those with colon tumours (1.09 versus
0.96 mmol/L, p = 0.05). Mean duration from diagnosis to
surgery was 7.4 weeks for all colorectal tumours but was
significantly different for colon cancer patients (5.1 weeks)
as compared to patients with rectum cancer (12.2 weeks).
Discussion
The present study firstly shows a high prevalence of preoper-
ative ID in colorectal cancer patients. Almost half of the pa-
tients with newly diagnosed colorectal cancer are iron deficient
at presentation. Interestingly, most patients have isolated FID
(15%) or a combination of FID and AID (81%), compared to
only 4% with isolated AID. From these results, we may con-
clude that the high percentage of patients with FID or a com-
ponent of FID suggests that inflammation plays an important
role in the development of iron deficiency in colorectal cancer
patients. Secondly, patients with an advanced tumour, ad-
vanced age, a tumour in the right colon and a high ASA clas-
sification are more prone to develop iron deficiency. Thirdly,
iron deficiency clearly plays a role in 80% of anemic patients
(5.2% AID, 9.6% FID, 65.2% combined AID and FID); how-
ever, iron deficiency is also encountered in 32%of non-anemic
patients (6.3% FID, 25.4% combined AID and FID).
In addition to the high prevalence of iron deficiency, the
clinical relevance of iron deficiency is studied in the present
study. Particularly, in univariable analysis, severe iron defi-
ciency is significantly associated with an increased postoper-
ative complication rate. Despite the fact that in the present
cohort, loss of significance is observed in multivariable anal-
ysis, most likely due to the relative small sample size, iron
deficiency still seems to be independently associated with
postoperative complications. Previous published studies
namely have demonstrated the efficacy of preoperative iron
supplementation with regard to reduction of the need for blood
transfusion and reduction of hospital length of stay [17, 18]. In
addition, lower total numbers of postoperative complications
were found. These results implicate iron deficiency as an
Table 4 Univariable and
multivariable logistic regression
analysis for risk factors of
postoperative complications
Univariable Multivariable
OR 95% CI p value OR 95% CI p value
Age (years) 1.02 0.99–1.05 0.074 1.01 0.99–1.04 0.336
Gender
Female versus male 0.38 0.22–0.67 0.001 0.38 0.21–0.68 0.001
ASA classification
III–IV versus I–II 2.08 1.15–3.76 0.016 1.71 0.87–3.36 0.118
Surgery
Laparoscopic versus open 0.34 0.17–0.68 0.002 0.29 0.13–0.62 0.002
Tumour localisation
Rectum versus colon 1.47 0.86–2.53 0.16 2.07 1.12–3.82 0.021
Severe iron deficiency at diagnosis 1.94 1.07–3.54 0.030 1.84 0.94–3.60 0.074
Table 5 Characteristics in colon versus rectum cancer patients
Colon Rectum p value
Number, n 239 100
Age (years) 0.15
Mean ± SD 70.2 ± 10.4 68.3 ± 11.6
Anaemia at diagnosis, % 41.8 15.0 < 0.001
Preoperative anaemia, % 45.1 20.6 < 0.001
Postoperative anaemia, % 76.2 65.0 0.04
Hb at diagnosisa
Mean ± SD 7.78 ± 1.4 8.54 ± 1.0 < 0.001
Preoperative Hb
Mean ± SD 7.87 ± 1.2 8.45 ± 0.9 < 0.001
Postoperative Hb
Mean ± SD 6.91 ± 1.1 7.34 ± 0.9 < 0.001
Reduction in Hb level due
to surgery
Mean ± SD 0.96 ± 0.6 1.09 ± 0.5 0.05
a In mmol/L
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attractive treatment target to at least ameliorate short-term
outcomes.
Preoperative anaemia is emerging as an important health
problem in colorectal cancer patients. Importantly, preopera-
tive anaemia has already been associated with increased short-
term postoperative morbidity and mortality (< 30 days) [2, 19]
and worse colorectal tumour prognosis [3, 4, 20]. Whereas
preoperative anaemia is often associated with iron deficiency,
up to now, guidelines for the management of cancer or
chemotherapy-induced anaemia make only a few remarks on
the management of iron deficiency.
The ASCO (American Society of Clinical Oncology) guide-
line [21] on the use of epoetin and darbepoietin in adult pa-
tients with cancer recommends to only start iron supplementa-
tion in order to improve the efficacy of erythropoietin-
stimulating agents (ESAs), and to monitor iron status during
the course of ESA therapy. The ESMO (European Society for
Medical Oncology) guideline [16] states that intravenous iron
therapy is more effective in terms of Hb optimisation as com-
pared to oral iron therapy and that iron therapy seems to reduce
the total number of patients receiving blood transfusions. Most
elaborate is the NCCN (National Comprehensive Cancer
Network) guideline [15] on cancer- and chemotherapy-
induced anaemia that recommends to start iron monotherapy
in absolute iron deficiency patients, independently of the pres-
ence of anaemia, to start iron therapy in patients receiving ESA,
and to withheld iron therapy in patients with active infections.
The NCCN guideline additionally briefly addresses treatment
of merely iron deficiency in non-anemic patients. This seems to
be clinically relevant as iron deficiency itself, in the absence of
anaemia, can cause symptoms as impaired physical function
and fatigue [22, 23]. The observed high prevalence of iron
deficiency in colorectal cancer patients causes the authors to
advise routinely monitoring of preoperative iron status.
In general, guidelines and literature stress the high thera-
peutic potential of iron therapy in patients with iron deficiency
anaemia to increase preoperative haemoglobin level, to lower
the need for blood transfusions and to improve short-term
postoperative outcomes. An important caveat raised by
ESMO is that oral—as opposed to intravenous—iron admin-
istration is quite ineffective in, as our study shows, the major
part of patients that have some form of FID. Inflammation-
related IL-6 increased hepcidin production namely hampers
iron absorption from the duodenum [8, 24]. Furthermore,
there is an increased uptake and retention of iron in macro-
phages, resulting in limitation of availability of iron for iron-
restricted erythropoiesis.
Notwithstanding its increased efficacy, timing and dosing are
crucial for intravenous iron therapy. Maximal Hb response
namely usually takes 4 to 6 weeks [25], while often more than
one dose, maximum of 1 gweekly (i.e. Ferinject orMonofer), is
required. As highlighted in our study, such an approach is well
feasible for patients with rectum tumours; however, for patients
with colon tumours with only on average a 5-week period be-
tween diagnosis and surgery, this would be quite a challenge.
Furthermore, preoperatively, anaemia was found in almost half
of all colon cancer patients, compared to only 20% of rectum
cancer patients. However, surgery-mediated blood loss and de-
crease in Hb level was substantially higher in rectum cancer
patients, with an increase in postoperative anaemia to 66%,
compared to 77% in colon cancer patients. This finding sug-
gests that an even more proactive approach to correct preoper-
ative anaemia in all rectal cancer patients seems to be warranted.
An additional comment, however, should be made. Despite
the increased use and success of preoperative—often intrave-
nous—iron therapy to correct anaemia, there are no clinical
studies addressing long-term effects of iron therapy in colo-
rectal cancer patients. The importance of this is highlighted by
the fact that iron is an important growth factor for rapidly
proliferating cells including bacteria and tumour cells. FID
in this regard is believed to be a potentially effective defense
strategy of the human body to inhibit the growth of pathogens.
Several experimental animal studies have shown that expo-
sure to iron can be a risk factor for developing colorectal
cancer and tumour growth [10, 26, 27]. While oral iron might
induce intraluminal tumour growth, intravenous iron could in
this respect additionally be a potential risk for stimulating
growth of metastases.
Ultimately, in preoperative blood management, the poten-
tial risks of blood transfusion and iron supplementation have
to be cautiously weighed up against the risks of anaemia and
iron deficiency. Importantly, concerning oncological patients,
not only short-term but also long-term oncological effects
have to be included in this risk assessment. Preoperative anae-
mia and blood transfusion have already been strongly associ-
ated with a worse oncological outcome [5, 28]. The oncolog-
ical effects of iron supplementation, however, have not been
studied yet. Therefore, clinical studies comparing the long-
term effects of anaemia and iron deficiency with the long-
term effects of iron supplementation and blood transfusion
are required to establish the optimal blood management strat-
egy in oncological patients.
Strengths and limitations
One of the strengths of the present study is the timing of
measuring iron status of patients. Iron status was measured
directly after colonoscopy, where a lesion suspicious of colo-
rectal cancer was noticed. As a result, in the vast majority, the
iron status we used was not yet affected by any iron supple-
mentation and therefore a reliable representation of condition
around diagnosis. The major limitation of this study was the
sample size. Therefore, in comparing characteristics of AID
and FID, and in assessing the association between iron defi-
ciency and postoperative complication, the small sample size
did not allow us to draw firm conclusion on associations. In
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addition, nonetheless, up till now, this is the largest group of
colorectal cancer patients in which the prevalence and type of
iron deficiency are described.
Conclusion
This study shows a high prevalence of preoperative iron defi-
ciency in colorectal cancer patients, including a high percent-
age of patients with—a component of—functional iron defi-
ciency, and frequently associated an increased postoperative
complication rate, anaemia, right-sided colon tumours, ad-
vanced age and tumour stage, and poor physical status. As
both types of iron deficiency require a different treatment strat-
egy, our results illustrate the therapeutic potential of especially
intravenous iron supplementation in patients with severe iron
deficiency and stress the urgency of routinely monitoring pre-
operative iron status and differentiation between types of iron
deficiency. As iron therapy may also be potentially harmful in
respect to stimulation of tumour growth, future clinical trials
assessing the long-term effect of iron therapy are necessary.
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